HUTCHMED Closes License Deal With GSK Outside China
HUTCHMED says customary closing conditions have been completed for its license of a KRAS-EGFR-antibody conjugate therapy to GSK outside China.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.